HIV Drugs Market 2018 Global Share, Trends, Challenges and Opportunities Research Report Forecast to 2025

HIV Drugs Market 2018 Global Share, Trends, Challenges and Opportunities Research Report Forecast to 2025

Wiseguyreports.Com Added New Market Research Report On -“Global HIV Drugs Market 2018 Top Manufacturers, Production , Growth and Future Demand Forecast to 2025 ”.     Global HIV Drugs Market WiseGuyRerports.com Presents “Global HIV Drugs Market Research Report 2018” New Document to its Studies Database. The Report Contain 99 Pages With Detailed Analysis. Description This […]

Daily aspirin may help keep HIV at bay, says University of Manitoba study

Daily aspirin may help keep HIV at bay, says University of Manitoba study

A readily available, low-cost drug may help prevent HIV transmission, according to a new study out of Winnipeg. Low-dose aspirin — the same used to help prevent cardiovascular disease — shows promise as a new way to help prevent HIV from transmitting from one person to the other, a University of Manitoba study has found. […]

Vatican makes progress on pushing drug availability for kids with HIV

Vatican makes progress on pushing drug availability for kids with HIV

By Paul Jeffrey • Catholic News Service • Posted August 9, 2018 AMSTERDAM (CNS) — An initiative to identify and properly treat children living with HIV has gained new momentum as international organizations and pharmaceutical companies respond to a Vatican push to look past profit to doing the right thing. Few children in the developed […]

Another 2-Drug HIV Antiretroviral Regimen Emerges

Another 2-Drug HIV Antiretroviral Regimen Emerges

Pedro Cahn, MD, PhD Not only is there a once-daily pill that can control HIV infection with just 2 drugs and fewer side effects than the customary 3- or 4-drug regimens, but there may also be a choice between those pills soon. In addition to the recently reported 100-week success with dolutegravir/rilpivirine (Juluca) as a […]

GSK publishes SWORD data on 2-drug HIV regimen

GSK publishes SWORD data on 2-drug HIV regimen

ViiV Healthcare, the HIV specialty firm of GlaxoSmithKline, presented 100-week results from its phase 3 clinical trials on a 2-drug regimen called Juluca (dolutegravir and rilpivirine) at the 22nd International AIDS Conference held in Amsterdam in July. Tivicay SWORD 1 and SWORD 2 studies proved the […]

Use HIV lessons to stem opioid epidemic

Use HIV lessons to stem opioid epidemic

While HIV transmission has been significantly reduced over the past decades — especially among people who inject drugs, who now represent less than 10 percent of new HIV diagnoses per year — the recent national surge in opioid misuse threatens to reverse some of these gains. In 2016, over 42,000 people died from overdose of […]